Serine phosphorylation and arginine methylation at the crossroads to neurodegeneration

Experimental Neurology

Volumn 271, Issue , 2015, Pages 77-83

  Basso, Manuela ^a   Pennuto, Maria ^a  

^a UNIVERSITY OF TRENTO   (Italy)

Author keywords

Arginine methylation; Neurodegenerative diseases; Protein arginine methyltransferase (PRMT); Protein kinase B (Akt); Serine phosphorylation

Indexed keywords

ANDROGEN RECEPTOR; ARGININE; POLYGLUTAMINE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN KINASE B; SERINE;

AMINO ACID ANALYSIS; BULBAR MUSCULAR ATROPHY; CONSENSUS SEQUENCE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METHYLATION; PROTEIN MISFOLDING; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SPINAL MUSCULAR ATROPHY; ANIMAL; METABOLISM; METHYLATION; PHOSPHORYLATION;

ANIMALS; ARGININE; HUMANS; METHYLATION; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; SERINE;

EID: 84929650719     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.05.003     Document Type: Review

References (71)

1. Ahn J.Y. Neuroprotection signaling of nuclear akt in neuronal cells. Exp. Neurobiol. 2014, 23:200-206.
2. Ajiro M., Katagiri T., Ueda K., Nakagawa H., Fukukawa C., Lin M.L., Park J.H., Nishidate T., Daigo Y., Nakamura Y. Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int. J. Oncol. 2009, 35:673-681.
3. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15:6541-6551.
4. Araya N., Hiraga H., Kako K., Arao Y., Kato S., Fukamizu A. Transcriptional down-regulation through nuclear exclusion of EWS methylated by PRMT1. Biochem. Biophys. Res. Commun. 2005, 329:653-660.
5. Bedford M.T., Clarke S.G. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 2009, 33:1-13.
6. Bertram L., Tanzi R.E. The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 2005, 115:1449-1457.
7. Brettschneider J., Del Tredici K., Lee V.M., Trojanowski J.Q. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat. Rev. Neurosci. 2015, 16:109-120.
8. Brunet A., Datta S.R., Greenberg M.E. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 2001, 11:297-305.
9. Chen H.K., Fernandez-Funez P., Acevedo S.F., Lam Y.C., Kaytor M.D., Fernandez M.H., Aitken A., Skoulakis E.M., Orr H.T., Botas J., Zoghbi H.Y. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 2003, 113:457-468.
10. Colin E., Regulier E., Perrin V., Durr A., Brice A., Aebischer P., Deglon N., Humbert S., Saudou F. Akt is altered in an animal model of Huntington's disease and in patients. Eur. J. Neurosci. 2005, 21:1478-1488.
11. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
12. Deng H., Gao K., Jankovic J. The VPS35 gene and Parkinson's disease. Mov. Disord. 2013, 28:569-575.
13. Du K., Arai S., Kawamura T., Matsushita A., Kurokawa R. TLS and PRMT1 synergistically coactivate transcription at the survivin promoter through TLS arginine methylation. Biochem. Biophys. Res. Commun. 2011, 404:991-996.
14. Duvick L., Barnes J., Ebner B., Agrawal S., Andresen M., Lim J., Giesler G.J., Zoghbi H.Y., Orr H.T. SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776. Neuron 2010, 67:929-935.
15. Ehrnhoefer D.E., Sutton L., Hayden M.R. Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 2011, 17:475-492.
16. Emamian E.S., Kaytor M.D., Duvick L.A., Zu T., Tousey S.K., Zoghbi H.Y., Clark H.B., Orr H.T. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 2003, 38:375-387.
17. Everett C.M., Wood N.W. Trinucleotide repeats and neurodegenerative disease. Brain 2004, 127:2385-2405.
18. Fackelmayer F.O. Protein arginine methyltransferases: guardians of the Arg?. Trends Biochem. Sci. 2005, 30:666-671.
19. Feng Y., Maity R., Whitelegge J.P., Hadjikyriacou A., Li Z., Zurita-Lopez C., Al-Hadid Q., Clark A.T., Bedford M.T., Masson J.Y., Clarke S.G. Mammalian protein arginine methyltransferase 7 (PRMT7) specifically targets RXR sites in lysine- and arginine-rich regions. J. Biol. Chem. 2013, 288:37010-37025.
20. Friedman M.J., Shah A.G., Fang Z.H., Ward E.G., Warren S.T., Li S., Li X.J. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat. Neurosci. 2007, 10:1519-1528.
21. Giovannone B., Lee E., Laviola L., Giorgino F., Cleveland K.A., Smith R.J. Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. J. Biol. Chem. 2003, 278:31564-31573.
22. Gonzalez E., McGraw T.E. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009, 8:2502-2508.
23. Herrmann F., Lee J., Bedford M.T., Fackelmayer F.O. Dynamics of human protein arginine methyltransferase 1(PRMT1) in vivo. J. Biol. Chem. 2005, 280:38005-38010.
24. Humbert S., Bryson E.A., Cordelieres F.P., Connors N.C., Datta S.R., Finkbeiner S., Greenberg M.E., Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2002, 2:831-837.
25. Jobert L., Argentini M., Tora L. PRMT1 mediated methylation of TAF15 is required for its positive gene regulatory function. Exp. Cell Res. 2009, 315:1273-1286.
26. Jorgensen N.D., Andresen J.M., Lagalwar S., Armstrong B., Stevens S., Byam C.E., Duvick L.A., Lai S., Jafar-Nejad P., Zoghbi H.Y., Clark H.B., Orr H.T. Phosphorylation of ATXN1 at Ser776 in the cerebellum. J. Neurochem. 2009, 110:675-686.
27. Katsuno M., Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Sang C., Kobayashi Y., Doyu M., Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002, 35:843-854.
28. Keryer G., Pineda J.R., Liot G., Kim J., Dietrich P., Benstaali C., Smith K., Cordelieres F.P., Spassky N., Ferrante R.J., Dragatsis I., Saudou F. Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease. J. Clin. Invest. 2011, 121:4372-4382.
29. Kim H.M., Kang D.K., Kim H.Y., Kang S.S., Chang S.I. Angiogenin-induced protein kinase B/Akt activation is necessary for angiogenesis but is independent of nuclear translocation of angiogenin in HUVE cells. Biochem. Biophys. Res. Commun. 2007, 352:509-513.
30. Kim J.D., Kako K., Kakiuchi M., Park G.G., Fukamizu A. EWS is a substrate of type I protein arginine methyltransferase, PRMT8. Int. J. Mol. Med. 2008, 22:309-315.
31. Kwiatkowski T.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., Valdmanis P., Rouleau G.A., Hosler B.A., Cortelli P., de Jong P.J., Yoshinaga Y., Haines J.L., Pericak-Vance M.A., Yan J., Ticozzi N., Siddique T., McKenna-Yasek D., Sapp P.C., Horvitz H.R., Landers J.E., Brown R.H. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
32. Lee Y.H., Stallcup M.R. Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol. Endocrinol. 2009, 23:425-433.
33. Lim J., Crespo-Barreto J., Jafar-Nejad P., Bowman A.B., Richman R., Hill D.E., Orr H.T., Zoghbi H.Y. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008, 452:713-718.
34. Lin H.K., Yeh S., Kang H.Y., Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7200-7205.
35. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
36. Nedelsky N.B., Pennuto M., Smith R.B., Palazzolo I., Moore J., Nie Z., Neale G., Taylor J.P. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 2010, 67:936-952.
37. Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 2007, 30:575-621.
38. Palazzolo I., Burnett B.G., Young J.E., Brenne P.L., La Spada A.R., Fischbeck K.H., Howell B.W., Pennuto M. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum. Mol. Genet. 2007, 16:1593-1603.
39. Palazzolo I., Stack C., Kong L., Musaro A., Adachi H., Katsuno M., Sobue G., Taylor J.P., Sumner C.J., Fischbeck K.H., Pennuto M. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009, 63:316-328.
40. Pardo R., Colin E., Regulier E., Aebischer P., Deglon N., Humbert S., Saudou F. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J. Neurosci. 2006, 26:1635-1645.
41. Park J., Al-Ramahi I., Tan Q., Mollema N., Diaz-Garcia J.R., Gallego-Flores T., Lu H.C., Lagalwar S., Duvick L., Kang H., Lee Y., Jafar-Nejad P., Sayegh L.S., Richman R., Liu X., Gao Y., Shaw C.A., Arthur J.S., Orr H.T., Westbrook T.F., Botas J., Zoghbi H.Y. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature 2013, 498:325-331.
42. Parodi S., Pennuto M. Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Front. Neuroendocrinol. 2011, 32:416-425.
43. Pennuto M., Palazzolo I., Poletti A. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum. Mol. Genet. 2009, 18:R40-R47.
44. Rangone H., Poizat G., Troncoso J., Ross C.A., MacDonald M.E., Saudou F., Humbert S. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur. J. Neurosci. 2004, 19:273-279.
45. Rappsilber J., Friesen W.J., Paushkin S., Dreyfuss G., Mann M. Detection of arginine dimethylated peptides by parallel precursor ion scanning mass spectrometry in positive ion mode. Anal. Chem. 2003, 75:3107-3114.
46. Ratovitski T., Arbez N., Stewart J.C., Chighladze E., Ross C.A. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's Disease (HD). Cell Cycle 2015.
47. Rinaldi C., Bott L.C., Chen K.L., Harmison G.G., Katsuno M., Sobue G., Pennuto M., Fischbeck K.H. IGF-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. Mol. Med. 2012, 18:1261-1268.
48. Sakamaki J., Daitoku H., Ueno K., Hagiwara A., Yamagata K., Fukamizu A. Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:6085-6090.
49. Salih D.A., Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr. Opin. Cell Biol. 2008, 20:126-136.
50. Scaramuzzino C., Monaghan J., Milioto C., Lanson N.A., Maltare A., Aggarwal T., Casci I., Fackelmayer F.O., Pennuto M., Pandey U.B. Protein arginine methyltransferase 1 and 8 interact with FUS to modify its sub-cellular distribution and toxicity in vitro and in vivo. PLoS One 2013, 8:e61576.
51. Scaramuzzino C., Casci I., Parodi S., Lievens P.M., Polanco M.J., Milioto C., Chivet M., Monaghan J., Mishra A., Badders N., Aggarwal T., Grunseich C., Sambataro F., Basso M., Fackelmayer F.O., Taylor J.P., Pandey U.B., Pennuto M. Protein arginine methyltransferase 6 enhances polyglutamine-expanded androgen receptor function and toxicity in spinal and bulbar muscular atrophy. Neuron 2015, 85:88-100.
52. Song G., Ouyang G., Bao S. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 2005, 9:59-71.
53. Soyal S.M., Felder T.K., Auer S., Hahne P., Oberkofler H., Witting A., Paulmichl M., Landwehrmeyer G.B., Weydt P., Patsch W. A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Hum. Mol. Genet. 2012, 21:3461-3473.
54. Takahashi Y., Daitoku H., Hirota K., Tamiya H., Yokoyama A., Kako K., Nagashima Y., Nakamura A., Shimada T., Watanabe S., Yamagata K., Yasuda K., Ishii N., Fukamizu A. Asymmetric arginine dimethylation determines life span in C. elegans by regulating forkhead transcription factor DAF-16. Cell Metab. 2011, 13:505-516.
55. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science 2002, 296:1991-1995.
56. Teyssier C., Ma H., Emter R., Kralli A., Stallcup M.R. Activation of nuclear receptor coactivator PGC-1alpha by arginine methylation. Genes Dev. 2005, 19:1466-1473.
57. Thandapani P., O'Connor T.R., Bailey T.L., Richard S. Defining the RGG/RG motif. Mol. Cell 2013, 50:613-623.
58. Tradewell M.L., Yu Z., Tibshirani M., Boulanger M.C., Durham H.D., Richard S. Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum. Mol. Genet. 2012, 21:136-149.
59. Tsuda H., Jafar-Nejad H., Patel A.J., Sun Y., Chen H.K., Rose M.F., Venken K.J., Botas J., Orr H.T., Bellen H.J., Zoghbi H.Y. The AXH domain of ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/senseless proteins. Cell 2005, 122:633-644.
60. van Haren M., van Ufford L.Q., Moret E.E., Martin N.I. Synthesis and evaluation of protein arginine N-methyltransferase inhibitors designed to simultaneously occupy both substrate binding sites. Org. Biomol. Chem. 2015, 13:549-560.
61. Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., Ganesalingam J., Williams K.L., Tripathi V., Al-Saraj S., Al-Chalabi A., Leigh P.N., Blair I.P., Nicholson G., de Belleroche J., Gallo J.M., Miller C.C., Shaw C.E. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1208-1211.
62. Wada K., Inoue K., Hagiwara M. Identification of methylated proteins by protein arginine N-methyltransferase 1, PRMT1, with a new expression cloning strategy. Biochim. Biophys. Acta 2002, 1591:1-10.
63. Wang J., Chen L., Sinha S.H., Liang Z., Chai H., Muniyan S., Chou Y.W., Yang C., Yan L., Feng Y., Li K.K., Lin M.F., Jiang H., Zheng Y.G., Luo C. Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation. J. Med. Chem. 2012, 55:7978-7987.
64. Warby S.C., Chan E.Y., Metzler M., Gan L., Singaraja R.R., Crocker S.F., Robertson H.A., Hayden M.R. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum. Mol. Genet. 2005, 14:1569-1577.
65. Warby S.C., Doty C.N., Graham R.K., Shively J., Singaraja R.R., Hayden M.R. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol. Cell. Neurosci. 2009, 40:121-127.
66. Weydt P., Pineda V.V., Torrence A.E., Libby R.T., Satterfield T.F., Lazarowski E.R., Gilbert M.L., Morton G.J., Bammler T.K., Strand A.D., Cui L., Beyer R.P., Easley C.N., Smith A.C., Krainc D., Luquet S., Sweet I.R., Schwartz M.W., La Spada A.R. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 2006, 4:349-362.
67. Wolf S.S. The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans. Cell. Mol. Life Sci. 2009, 66:2109-2121.
68. Yamagata K., Daitoku H., Takahashi Y., Namiki K., Hisatake K., Kako K., Mukai H., Kasuya Y., Fukamizu A. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol. Cell 2008, 32:221-231.
69. Yang L., Sun M., Sun X.M., Cheng G.Z., Nicosia S.V., Cheng J.Q. Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine 212. J. Biol. Chem. 2007, 282:10981-10987.
70. Zimprich A., Benet-Pages A., Struhal W., Graf E., Eck S.H., Offman M.N., Haubenberger D., Spielberger S., Schulte E.C., Lichtner P., Rossle S.C., Klopp N., Wolf E., Seppi K., Pirker W., Presslauer S., Mollenhauer B., Katzenschlager R., Foki T., Hotzy C., Reinthaler E., Harutyunyan A., Kralovics R., Peters A., Zimprich F., Brucke T., Poewe W., Auff E., Trenkwalder C., Rost B., Ransmayr G., Winkelmann J., Meitinger T., Strom T.M. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 2011, 89:168-175.
71. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.